Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial
Randomized controlled trial published in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2006)
Abstract
BACKGROUND: The hygiene hypothesis is often proposed to explain the high prevalence of atopy in the western world. Dysregulation of the immune system may result from inadequate exposure to micro-organisms such as mycobacteria. A small trial suggested that a killed extract of Mycobacterium vaccae ameliorates atopic dermatitis (AD). OBJECTIVES: To confirm in a large clinical trial whether killed M. vaccae ameliorates AD in 5-16-year-old children. METHODS: This was a randomized, placebo-controlled, double-blind, multi-centre study of the effect of intradermal injection of killed M. vaccae (0.1 or 1 mg) on patients, aged 5-16, with moderate-to-severe AD. Patients were followed up for 24 weeks. The primary end point was the change in severity of AD at 12 weeks, assessed using the six area, six-sign, atopic dermatitis (SASSAD) score. Secondary end points included changes in disease extent, patient's global assessment and children's dermatology life quality index. RESULTS: There were 166 patients randomized. The mean SASSAD score fell to a similar degree at week 12 in all treatment arms: from 33 to 24, (26%) in the high-dose group, from 30 to 23 (25%) in the low-dose group and from 36 to 27 (24%) in the placebo group (P>0.05). Secondary end points followed the same trend. Adverse events were generally those expected to occur in this population. Injection site reactions occurred in 32 patients at week 4. CONCLUSIONS: M. vaccae was no more effective than the placebo in ameliorating the severity of AD.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
The hygiene hypothesis is often proposed to explain the high prevalence of atopy in the western world.
Por qué esto importa para la hirudoterapia
Este ensayo multicéntrico aleatorizado, doble ciego, controlado con placebo evaluó si una suspensión inactivada de Mycobacterium vaccae inyectada por vía intradérmica podría mejorar la dermatitis atópica de moderada a grave en niños de 5–16 años, con el cambio en la puntuación de severidad SASSAD a las 12 semanas como variable principal. Todas las ramas de tratamiento mostraron una mejoría similar (~24–26% de reducción), sin diferencia estadísticamente significativa entre M. vaccae (dosis alta o baja) y placebo. Este artículo no tiene conexión con sanguijuelas, hirudoterapia, hirudina o el secretoma de la sanguijuela. No existe una relevancia defendible para el dominio de ASH; el estudio es un ensayo de inmunoterapia para la dermatitis atópica infantil sin contenido alguno sobre anticoagulantes ni relacionado con sanguijuelas.
Citación
Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial
Berth-Jones J et al. · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2006
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026